Introduction
Huma is a London-headquartered digital health company founded in 2011 that operates a regulated, disease-agnostic cloud platform spanning remote patient monitoring, decentralized clinical trials, virtual wards, and AI-first care modules across more than 70 countries. Dan Vahdat founded Huma and serves as chief executive officer per the company’s about page and March 20, 2026 newsroom announcement reviewed in July 2026.
Huma’s scale — roughly 500 employees, $250 million raised, and engagement with more than 50 million individuals per its about disclosures — distinguishes it from point-solution RPM vendors by offering configurable infrastructure health systems and pharma sponsors assemble rather than bespoke project builds.
What the company does
Huma Therapeutics provides the Huma Cloud Platform: modular digital health infrastructure with pre-built eConsent, ePRO, eCOA, and remote monitoring components health customers configure without hard coding. The platform holds FDA 510(k) Class II and EU MDR Class IIb certifications, supporting deployments from NHS virtual wards to pharmaceutical decentralized trials including COVID-19 studies and Our Future Health research cited in UK government review materials Huma references.
March 2026 brought Huma Intelligence Scribe — an AI-powered consultation documentation tool built on NVIDIA Nemotron speech models and NVIDIA-optimized Llama embedding models. The scribe produces separate patient-friendly and clinician summaries from real-time transcription, supporting 25 languages to address U.S. care equity barriers Vahdat emphasizes in the release.
Who it serves
Huma serves national health systems, pharmaceutical clinical development teams, governments, and provider networks deploying population-scale digital care. Early Huma Intelligence Scribe adoption centers on U.S. respiratory therapy — 38 active therapists and approximately 2,250 patients generating roughly 2,300 live interaction notes monthly per the March 2026 release, demonstrating structured follow-up documentation for complex chronic respiratory populations.
Life-sciences buyers evaluate Huma on regulatory certification breadth, trial setup speed, and ability to unify care and research data on one platform rather than siloed eClinical and RPM vendors.
Company background
Vahdat founded Huma in London in 2011 with a mission to shift medicine from reactive to proactive care through scalable digital and AI tools. The company grew from patient-facing apps into enterprise cloud infrastructure, raising over $250 million including a Series D exceeding $80 million tied to GenAI-integrated Huma Cloud Platform launches. Millbank Tower in Westminster remains global headquarters while Huma operates offices across San Francisco, New York, Frankfurt, and other locations on its about page.
Product and AI capabilities
Huma’s AI strategy spans population health analytics, CVD AI screening modules, and the 2026 Intelligence Scribe documentation layer. The scribe uses NVIDIA infrastructure for automatic speech recognition, speaker identification, and summarization — producing actionable clinical insights alongside patient-readable explanations. Vahdat describes the platform analogy as Shopify for digital health: lowering build cost so digital care becomes affordable across income levels.
Multilingual scribe support matters for U.S. health equity — documentation quality should not degrade when consultations occur in languages beyond English, a design choice Huma highlights against monolingual ambient documentation competitors.
Key developments
2011: Huma founded in London by Dan Vahdat. Series D financing exceeding $80M with Huma Cloud Platform GenAI integrations announced. March 20, 2026: Huma Intelligence Scribe launched with NVIDIA AI, reporting U.S. respiratory care adoption metrics (huma.com newsroom, official source). 2026: Platform supports 4,500+ hospitals and clinics per scribe release disclosures.
Why it matters
Huma matters because digital health procurement is splitting between single-disease RPM apps and platform plays that survive payer consolidation. Huma’s regulated cloud substrate plus 2026 NVIDIA scribe launch tests whether documentation AI extends platform value into clinical encounters — a different motion than imaging AI from Qure.ai or ambient scribes from U.S.-only vendors. UK-headquartered Huma also anchors Brel’s European digital health coverage alongside Oxford imaging companies.
Sector context
Huma belongs in Brel’s AI in healthcare coverage under digital health and remote monitoring, related to clinical trial technology and AI documentation infrastructure. Readers comparing Huma to biotech AI should note Huma’s strength is care delivery and research operations software rather than drug discovery — a category served by companies like BenchSci.
Sources and references
Huma Intelligence Scribe newsroom article (March 20, 2026) and About Huma page.
- Huma — Intelligence Scribe NVIDIA launch (huma.com, March 20, 2026)
- Huma — About Huma (huma.com)
Reviewed July 10, 2026. Dan Vahdat is founder and CEO.